ArticleArchives of endocrinology and metabolism2025
Effect of radioiodine treatment for Graves' disease on the generation of TSH anti-receptor stimulating antibodies (TSI).
Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is well established that serum levels of TSH receptor antibodies (TRAb) rise after radioiodine (131I) therapy for Graves' disease (GD). However, it remains unclear whether these post-therapy autoantibodies are predominantly TSH receptorstimulating immunoglobulins (TSI) and how their persistence might affect treatment outcomes. SUBJECTS AND
methodsIn this prospective study, 39 patients with GD underwent 131I therapy. Serum TRAb (measured by competitive electrochemiluminescence, ECLIA) and TSI (measured by an IMMULITE® 2000/2000 XPi TSI assay) were evaluated at baseline and at 1, 2, 3, 6, 9, and 12 months post-therapy. More than 7% increase from baseline was considered a significant rise.
resultsAt diagnosis, all 39 patients tested positive for TRAb, while 38 tested positive for TSI. Both TRAb and TSI levels rose significantly between months 2 and 4 post-131I, followed by a progressive decline by months 9 to 12. TSI increased in 72% of patients; of these, 93% showed a gradual decrease but remained higher than baseline in 58% at 12 months. Patients with thyroid eye disease (TED), longer disease duration, or higher baseline TSI more frequently exhibited persistent elevation at one year. Despite the persistence of TSI, all patients achieved control of thyrotoxicosis (euthyroid or hypothyroid states).
conclusionRadioiodine therapy leads to an increase in TSI, which can remain elevated for up to 12 months in more than half of GD patients. These findings suggest potential benefits of measuring TSI for guiding management decisions, particularly regarding antithyroid drug discontinuation and pregnancy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.